Details

Autor(en) / Beteiligte

• Matyas, Csaba
• Trojnar, Eszter
• Zhao, Suxian
• Arif, Muhammad
• Mukhopadhyay, Partha
• Kovacs, Attila
• Fabian, Alexandra
• Tokodi, Marton
• Bagyura, Zsolt
• Merkely, Bela
• Kohidai, Laszlo
• Lajko, Eszter
• Takacs, Angela
• He, Yong
• Gao, Bin
• Paloczi, Janos
• Lohoff, Falk W
• Haskó, György
• Ding, Wen-Xing
• Pacher, Pal

Titel

PCSK9, A Promising Novel Target for Age-Related Cardiovascular Dysfunction

Ist Teil von

• JACC. Basic to translational science, 2023-10, Vol.8 (10), p.1334-1353

Ort / Verlag

United States: Elsevier

Erscheinungsjahr

2023

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• Cardiovascular diseases (CVDs) are the leading cause of death among elderly people. Proprotein convertase subtilisin/kexin type 9 (PCSK9) is an important regulator of cholesterol metabolism. Herein, we investigated the role of PCSK9 in age-related CVD. Both in humans and rats, blood PCSK9 level correlated positively with increasing age and the development of cardiovascular dysfunction. Age-related fatty degeneration of liver tissue positively correlated with serum PCSK9 levels in the rat model, while development of age-related nonalcoholic fatty liver disease correlated with cardiovascular functional impairment. Network analysis identified PCSK9 as an important factor in age-associated lipid alterations and it correlated positively with intima-media thickness, a clinical parameter of CVD risk. PCSK9 inhibition with alirocumab effectively reduced the CVD progression in aging rats, suggesting that PCSK9 plays an important role in cardiovascular aging.